What if there were an actual fountain of youth? What if it delivered a new, true, non-invasive “age reversing” solution for wrinkles, sagging, under-eye bags and circles, baldness, and other high-anxiety skin issues? Introducing The Gene Facelift™. If approved by the FDA, this is the easiest and most effective “Yes!” in anti-aging skin therapy to date for both doctors and patients.
Toxins paralyze. Fillers plump. Other technologies ‘fry’ the skin. And most current options are invasive and painful. The Gene Facelift™ is a non-invasive topical treatment of non-viral DNA. The topical application allows for ease of access and low patient burden.
Funded in part by the National Institutes of Health (NIH), The Gene Facelift™ is the first patented drug candidate to potentially regenerate aged, thin skin, reducing wrinkles, sagging, and other aesthetic and high-anxiety concerns.
The Gene Facelift™ is a non-invasive topical treatment of non-viral DNA. The topical application allows for ease of access and low patient burden.
Preclinical data shows The Gene Facelift™ rapidly triples skin thickness, regenerating collagen, elastin, and skin stem cells.
The Gene Facelift™ is designed to be redosable, and could boost clinic profits by as much as 400% compared to current toxin treatments.
The company's patented gene therapy is the first of its kind potential solution that reverses skin aging, regenerates collagen, and significantly thickens skin - by a never before achieved 300% increase in preclinical studies - potentially eliminating wrinkles, under-eye bags, crow's feet, sagging skin, and other cosmetic concerns on the cellular level.
GENIE Therapeutics has developed a multi-drug Platform Technology that may lead to multiple drug creations and launches from the same advanced DNA core, each one being a multibillion-dollar opportunity including wrinkles, hair loss, medical dermatology, and wound care.
Supported with NIH research funding¹ and guided by the company's team of ex-FDA veteran employee insiders to help advance FDA approval process steps. It is important to note that approvals for aesthetic drugs are generally less tedious than other drugs. In fact, we are not aware of an aesthetic drug candidate that was never successfully approved.
Just three of the markets that GENIE Therapeutics is targeting (non-invasive aesthetics treatments, medical dermatology, and wound care) represent a total addressable market of $101 Billion.
Danaher, ranked #132 on the Fortune 500 and part of the S&P 100, is a shareholder in GENIE Therapeutics. The company has formed a strong licensing partnership with Danaher for future high-yield HyperGRO™ GMP drug manufacturing. Danaher is highly qualified to meet all FDA GMP and CMC manufacturing requirements.
Because The Gene Facelift™ is a topical aesthetic drug, the cost associated with potential FDA development and approval is estimated at ~$30 million, much lower than other drugs used systemically for diseases such as cancer or heart disease.
One topical treatment shows significant regeneration of new elastin, collagen, stem cells, and skin thickness. GNE-142 regenerated a 300% increase in skin thickness – never before seen molecular age reversal results. This breakthrough Platform, developed with Johns Hopkins and NIH funding, has blockbuster potential to create multiple drugs from the same advanced DNA core. With revolutionizing aesthetics, it can be used across all full-body aesthetic skin conditions.
The GENIE multi-drug Platform Technology is capable of addressing numerous high-prevalence disease states within multiple billion-dollar markets.
The GENIE team has extensive experience in aesthetics and dermatology, FDA regulatory approvals, and experience building businesses with exits.
Founder & CEO
Shareholder & Scientific Advisor
Shareholder & Advisor
PRESIDENT
Cassondra Todd is an extraordinary marketer proven by an unparalleled track record of growing, directing and managing top-tier plastic surgery practices and providers in southern California. Her decades long series of successful
FDA Scientific Advisor
Ex-FDA Medical Officer employee (22+ years). Regulation of clinical trials of cellular and gene therapies including Aesthetic new drug applications. Graduate of Harvard Medical School. Prior Professor of Medicine at the Albert Einstein College of Medicine.
FDA Scientific Advisor
GENIE Therapeutics has a catalyst-rich pipeline powered by our multi-drug Platform Technology with numerous value drivers pending FDA guidance. We are positioned to deliver significant value creation through numerous programs with near-term inflection points. Our potential timeline to commercialization:
OFFERING TYPE
MINIMUM INVESTMENT
PRICE PER SHARE
TARGET RAISE
VALUATION CAP
EXIT STRATEGIES
The purpose is to raise funds to develop The Gene Facelift™️ and other drugs and to pursue FDA clinical trials. Using our platform, we also intend to develop and launch a non-drug skin line.
The minimum investment is $25,000 and there is no maximum amount.
Shares are issued within 7 days of your investment being funded. Shares are issued by our transfer agent V Stock Transfer. You will receive an email notification with instructions from V Stock Transfer.
Yes. You can invest using an IRA or through a trust account. When going through the investment questionnaire, you will select your preferred method of investing.
While there is no guarantee of going public, our potential strategy is to go public within 18-36 months as we achieve FDA milestones and we are already in talks with investment banks.
Yes! We plan to possibly give our investors early access to GENE Facelift™️ and other GENIE Therapeutics products before the general public. Investors will also receive additional discounts on products (to be determined).
Yes. You can access the GENIE Therapeutics Data Room here.
We have filed a Reg D 506c exemption which requires all investors to be accredited. An accredited investor is an individual with $200,000 in income for the past two years or a couple with a combined $300,000 in income or who has a $1M net worth excluding their primary residence. You may also qualify by holding certain licenses.
When you invest in shares in a private company like GENIE Therapeutics the shares are locked up for 12 months. After 12 months you can sell your shares to a qualified investor. You can also hold your shares and in the event GENIE Therapeutics is acquired or goes public you will have the option to sell your shares then.
GENIE Therapeutics is pioneering aesthetic gene therapies. This breakthrough multi-drug Platform Technology, developed with Johns Hopkins and NIH funding, if FDA approved, has blockbuster potential.
This site is not a part of the Facebook website or Facebook Inc. Additionally, this is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, INC.
This website contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this website, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: our ability to raise sufficient capital to execute our business plan; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations or ability to enter into marketing and other partnership agreements; expectations or ability to enter into product acquisition and in-licensing transactions; expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates; acceptance of our products by doctors, patients or payors; our ability to compete against other companies and research institutions; our ability to secure adequate protection for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; expected losses; and expectations for future capital requirements. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise thereafter, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.